https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)2018-06-03 00:00:002018-06-03 00:00:00Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e15174)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e15174)2018-06-01 00:00:002018-06-01 00:00:00The effect of Newcastle disease virus on tumor proliferation and cellular immunity.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e17515)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e17515)2018-06-01 00:00:002018-06-01 00:00:00Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-01 / Open Med (Wars) 2018;13:83-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-01 / Open Med (Wars) 2018;13:83-892018-06-01 00:00:002018-06-01 00:00:00The Efficacy of Radiofrequency Hyperthermia Combined with Chemotherapy in the Treatment of Advanced Ovarian Cancer
